KRYS

Krystal Biotech
KRYS

Last Price

Financial Snapshot

gainify

Market Data

Market Cap
$3.80B
EV
$3.04B
Shares Outstanding
29.56M
Beta
0.78

Wall Street View

Analyst Rating
BUY
Analyst Target Price
$211.20
P/E 2025E
23.38x
P/Revenue 2025E
9.10x

Price Dynamic

Price

%

1M

3M

6M

1Y

3Y

5Y

Peers

gainify

About Krystal Biotech, Inc.

gainify
KRYS

Krystal Biotech, Inc.

KRYS

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystr...

Sector

Healthcare

Industry

Biotechnology

CEO

Krishnan, Krish

Employees

275

IPO Date

2017-09-20

Headquarters

2100 Wharton Street, Suite 701, Pittsburgh, Pennsylvania, 15203, United States

gainify
Send us an emailFollow us on XConnect with us on LinkedInFollow us on InstagramFollow us on Threads
powered-by-sp

Market data is sourced from S&P Global Market Intelligence. All insights and analysis are developed by Gainify. Copyright © 2025, S&P Global Market Intelligence. All rights reserved.

View Data Providers

NEWSLETTER

Gainify provides tools and content designed to help users explore and understand the world of investing. All information available through our platform is for educational and informational use only. It is not intended as financial, investment or legal advice, and should not be treated as a recommendation or endorsement of any investment approach.
Our content is general in nature and does not account for your personal financial circumstances. Any investment decisions you make are your responsibility. We strongly recommend speaking with a licensed financial advisor or professional before acting on any information found on Gainify. Before using Gainify, please review our Terms of Service.

© 2025 Gainify. All rights reserved.